Drugmaker faced antitrust charges over 2013 Synacthen purchase.
- MarketWatch•2 days ago
Novartis CEO Joseph Jimenez spoke to WSJ's Deborah Ball about the impact that a Trump presidency could have on the pharmaceutical industry.
- Market Realist•3 days ago
The overall contribution of the innovative medicines segment was ~67% at $8,173 million for 3Q16.
NVS : Summary for Novartis AG Common Stock - Yahoo Finance
Novartis AG (NVS)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||70.23 - 70.88|
|52 Week Range||66.93 - 83.58|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||24.83|
|Dividend & Yield||2.72 (3.78%)|
|1y Target Est||N/A|